Goldman Sachs analyst Chris Shibutani maintained a Buy rating on BioNTech SE (BNTX – Research Report) today and set a price target of $137.00. The company’s shares closed last Friday at $99.72. Don't ...

Tazeen Ahmad, an analyst from Bank of America Securities, maintained the Buy rating on BioNTech SE (BNTX – Research Report). The associated price target remains the same with $150.00. Don't Miss our ...

Fintel reports that on November 8, 2024, Goldman Sachs upgraded their outlook for BioNTech SE - Depositary Receipt () ...

BioNTech SE BNTX announced that it has entered into a definitive agreement to acquire China-based biotech, Biotheus, to strengthen its oncology pipeline. With the acquisition, BNTX will gain full ...

BioNTech SE BNTX announced that it has entered into a definitive agreement to acquire China-based biotech, Biotheus, to strengthen its oncology pipeline. With the acquisition, BNTX will gain full ...

BioNTech (NASDAQ:BNTX) said it has agreed to buy bispecific antibody developer Biotheus for up to $950M, including $150M in potential milestone payments. Under the deal, BioNTech (BNTX ...

Last Friday, Palantir (PLTR) announced the transfer of its Class A stock to the Nasdaq (QQQ) from the New York Stock Exchange ...

BioNTech SE (NASDAQ:BNTX) reported a significant increase in total revenues for Q3 2024, reaching approximately EUR1.245 billion, up from EUR895 million in the same period last year. The company ...